Official websites use .gov
Secure .gov websites use HTTPS
Titles
- High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia1
- How Medicaid and CHIP shield children from the rising costs of prescription drugs1
- How does the Trump Administration drug pricing blueprint affect Medicaid?1
- How prescription drug use affects health care utilization and spending by older Americans: a review of the literature1
- How state Medicaid programs are managing prescription drug costs: results from a state Medicaid pharmacy survey for state fiscal years 2019 and 20201
- How to strengthen the Medicaid Drug Rebate Program to address rising Medicaid prescription drug costs1
- How will the Medicare Part D benefit change under current law and leading proposals?1
- Indication-specific pricing of pharmaceuticals in the United States health care system: a report from the 2015 ICER Membership Policy Summit1
- Making drug costs more transparent to consumers: a summary for policymakers1
- Manufacturers may need additional guidance to ensure consistent calculations of average sales prices1
- Medicaid's most costly outpatient drugs1
- Medicare Part B drug payments: impact of price substitutions based on 2014 average sales prices1
- Medicare Part B drug payments: impact of price substitutions based on 2015 average sales prices1
- Medicare Part B drug payments: impact of price substitutions based on 2016 average sales prices1
- Medicare Part B drug payments: impact of price substitutions based on 2017 average sales prices1
- Medicare Part B drug payments: impact of price substitutions based on 2020 average sales prices1
- Medicare Part B drug payments: impact of price substitutions based on 2021 average sales prices1
- Medicare Part B: Medicare represented at least half of the market for 22 of the 84 most expensive drugs in 2015 : report to Congressional requesters1
- Medicare Part D1
- Medicare Part D: CMS should monitor effects of rebates on plan formularies and beneficiary spending : report to congressional requesters1